skip navigation

Skip Nav

AIDSinfo Drug Database

AIDSinfo Drug Database

Drugs by class

FDA-approved

Investigational

Enfuvirtide  Audio icon

Brand Name: Fuzeon
Other Names: T-20
Drug Class: Entry and Fusion Inhibitors
Approved Use: Treatment of HIV Infection
Drug Image:
Click image to enlarge
Enfurvirtide
Chemical Image:
Click image to enlarge
enfuvirtide
enfuvirtide
Molecular Weight: 4491.9149

Information Type

WARNING:

Enfuvirtide causes injection site reactions. Almost all people get injection site reactions with enfuvirtide, which usually are mild to moderate but occasionally can be severe. Reactions on the skin where enfuvirtide is injected include:

  • Itching.
  • Swelling.
  • Redness.
  • Pain or tenderness.
  • Hardened skin.
  • Bumps.

Contact your health care provider right away if you have signs of infection at an injection site (oozing, increasing heat, swelling, redness, or pain).

Enfuvirtide can cause serious side effects. These include severe allergic reaction and possibly pneumonia.

Contact your health care provider right away if you have any of the following symptoms that could be signs of a severe allergic reaction:

  • Trouble breathing.
  • Fever with vomiting and a skin rash.
  • Blood in your urine.
  • Swelling of your feet.

Contact your health care provider right away if you have any of the following symptoms that could be signs of pneumonia:

  • Cough.
  • Fever.
  • Trouble breathing.

While taking enfuvirtide, it is important to keep all of your appointments with your health care provider.

What is enfuvirtide?

Enfuvirtide is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults and children 6 years of age and older. Enfuvirtide is for people who have not responded well enough to treatment with other HIV medicines. Enfuvirtide is always used in combination with other HIV medicines.

Enfuvirtide belongs to a class (group) of HIV drugs called entry and fusion inhibitors. Entry and fusion inhibitors block HIV from getting into and infecting certain cells of the immune system. This prevents HIV from multiplying and can reduce the amount of HIV in the body.

By attaching to the gp41 protein on the outer surface of HIV, enfuvirtide blocks HIV from getting into and infecting the immune cells. 
 
HIV medicines can’t cure HIV/AIDS, but taking a combination of HIV medicines (called an HIV regimen) every day helps people with HIV live longer, healthier lives. HIV medicines also reduce the risk of HIV transmission.

What should I tell my health care provider before taking enfuvirtide?

Before taking enfuvirtide, tell your health care provider:

  • If you are allergic to enfuvirtide or any other medicines.
  • If you have any other medical conditions.
  • If you are pregnant or plan to become pregnant. Whether enfuvirtide can harm an unborn baby is unknown. Talk to your health care provider about possible risks with taking enfuvirtide when pregnant.  
  • If you are breastfeeding or plan to breastfeed. Do not breastfeed if you are infected with HIV or are taking enfuvirtide.
  • About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Enfuvirtide may affect the way other medicines or products work, and other medicines or products may affect how enfuvirtide works.

How should I take enfuvirtide?

Enfuvirtide comes in powder form and is given as an injection (a shot). Each vial contains 108 mg of enfuvirtide powder. The enfuvirtide powder and everything needed to give the injection come in a convenience kit. The kit includes:

  • 60 vials of enfuvirtide powder.
  • 60 vials of sterile water for injection.
  • 60 syringes for mixing.
  • 60 syringes for injecting.
  • Injection instructions.
  • Patient information about enfuvirtide.

Take enfuvirtide according to your health care provider’s instructions. You or your caregiver should be trained by a health care provider on how to mix and inject enfuvirtide before injecting it. If you are having a hard time mixing or injecting enfuvirtide, contact your health care provider.

Enfuvirtide should be injected under the skin in the upper arm, upper leg, or stomach two times a day. Do not inject enfuvirtide in the same area as you did the time before. Do not inject enfuvirtide into the following areas: near the elbow, knee, groin, or lower or inner buttocks; directly over a blood vessel; around the belly button, scar tissue, a bruise, a mole, a surgical scar, a tattoo, or a burn site; or where there is an injection site reaction.

If enfuvirtide is foamy or jelled, allow more time for it to dissolve. Do not inject enfuvirtide if you see particles floating in the vial after it has been mixed. Enfuvirtide can be taken with or without food. Do not swallow enfuvirtide; it must be injected.

After injecting enfuvirtide, place used syringes in a special disposal container (called a sharps container). Do not place used syringes in a trash can.

Always take enfuvirtide in combination with other HIV medicines.

If you take too much enfuvirtide, contact your health care provider or local poison control center (1-800-222-1222) right away, or go to the nearest hospital emergency room.

For more information on how to take enfuvirtide, see the FDA drug label from DailyMed. (DailyMed is a federal website that includes the most recent drug labels submitted to FDA.)

What should I do if I forget a dose?

Take the missed dose as soon as you remember it. But if it is almost time for your next dose, skip the missed dose and just take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.

What side effects can enfuvirtide cause?

Enfuvirtide can cause serious side effects. These include severe allergic reaction, severe or infected injection sites, and possibly pneumonia. (See the WARNING above.)

Other possible side effects of enfuvirtide include:

  • Injection site reactions, including itching, swelling, redness, pain or tenderness, hardened skin, or bumps. If the injection site reaction is severe or you have signs of infection at an injection site (oozing, increasing heat, swelling, redness, or pain), contact your health care provider right away.
  • Shooting nerve pain or tingling that lasts up to 6 months. This is likely caused by injecting close to large nerves or near joints. (This side effect has been reported with use of the Biojector 2000 needle-free device to inject enfuvirtide.)
  • Bruising and/or collection of blood under the skin. (This side effect has also been reported with use of the Biojector 2000 needle-free device.)
  • Changes in the immune system (immune reconstitution inflammatory syndrome [IRIS]). IRIS can be mild or life-threatening.

Tell your health care provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of enfuvirtide. To learn more about possible side effects of enfuvirtide, read the drug label or package insert or talk to your health care provider or pharmacist.

The AIDSinfo fact sheet on HIV Medicines and Side Effects also includes information that may apply to enfuvirtide.

You can also report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088) or online at https://www.accessdata.fda.gov/scripts/medwatch/.

How should enfuvirtide be stored?

  • Enfuvirtide vials that are not mixed with sterile water can be stored at room temperature, 59°F to 86°F (15°C to 30°C). Enfuvirtide should be refrigerated if it cannot be stored at room temperature.
  • The sterile water can be stored at room temperature, 59°F to 86°F (15°C to 30°C).
  • After enfuvirtide has been mixed with sterile water, the vial can be stored in a refrigerator for up to 24 hours.
  • Follow FDA’s guidelines to safely dispose of enfuvirtide that is no longer needed or expired (out of date). 
  • Keep enfuvirtide and all medicines out of reach of children.

Where can I find more information about enfuvirtide?

More information about enfuvirtide is available:

Manufacturer Information

Hoffman-La Roche; Genentech
888-835-2555; 877-436-3683

The above Patient Version drug summary is based on the following FDA label(s): Kit.

Last Reviewed: October 15, 2014

Last Updated: October 15, 2014


Back to Top